PRF Versus Emdogain for Class II Furcation Defects of Mandibular Molars

This study evaluated the regenerative potential of platelet-rich fibrin (PRF) compared with enamel matrix derivative (Emdogain®) in the surgical treatment of Class II (F2) furcation defects of mandibular molars. Twenty-one systemically healthy patients with a total of 30 mandibular molars presenting with buccal Class II furcation defects were included. The furcation defects were treated surgically with either PRF or Emdogain®. Clinical parameters, including periodontal probing depth, clinical attachment level, bleeding on probing, and furcation involvement, were assessed before treatment and during follow-up. Clinical and radiographic measurements of the furcation defects were also performed. The main follow-up evaluation was conducted 6 months after surgery. The study compared the clinical and radiographic outcomes of PRF and Emdogain® in the treatment of mandibular molars with Class II furcation defects.

Inclusion Criteria: * Systemically healthy individuals * Stage III or Stage IV periodontitis * without allergies. Exclusion Criteria: * Smoking * Inadequate plaque control * Systemic diseases that may compromise periodontal therapy, including diabetes, immunodeficiency, or viral diseases. * Immunosuppressive therapy. * Treatment with bisphosphonates. * Treatment with anticoagulants. * Treatment with antiplatelet agents. * Thrombocytopenia. * Hypofibrinogenemia. * Hemophilia. * Other coagulation disorders. * Pregnancy. * Breastfeeding.